{"id":"C2004L04917","name":"Health Insurance (1990-91 Pathology Services Table) Regulations","slug":"health-insurance-1990-91-pathology-services-table-regulations","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":"343 of 1990","makingDate":null,"administeringDepartment":null,"currentVersion":{"id":27723,"registerId":"commonwealth-C2004L04917-current","compilationNumber":null,"startDate":"2026-04-01","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Health Insurance (1990-91 Pathology Services Table) Regulations","content":"![Commonwealth Coat of Arms of Australia](image.001.jpeg)\n\nStatutory Rules 1990 No. 3431\n\n–––––––\n\nHealth Insurance (1990-91 Pathology\n\nServices Table) Regulations\n\nI, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the Health Insurance Act 1973.\n\nDated 25 October 1990.\n\nBILL HAYDEN\n\nGovernor-General\n\nBy His Excellency’s Command,\n\nB. HOWE\n\nMinister of State for Community Services\n\nand Health\n\n–––––––––\n\nCitation\n\n1. These Regulations may be cited as the Health Insurance (1990-91 Pathology Services Table) Regulations.\n\nCommencement\n\n2. These Regulations commence on 1 November 1990.\n\nRepeal\n\n3. Statutory Rules 1990 No. 312 are repealed.\n\n \n\nPathology services table\n\n4. The following table of pathology services is prescribed for the purposes of subsection 4a (2) of the Health Insurance Act 1973:\n\nPATHOLOGY SERVICES TABLE\n\nRULES OF INTERPRETATION\n\n1. In this table:\n\n“Division” means a Division of the list of services and fees in this table;\n\n“item” means an item in that list;\n\n“recognised pathologist” means a medical practitioner who under a determination under section 61, is recognised for the purposes of this Act as a specialist in the specialty of pathology.\n\n2. If an item includes the symbol “(SP)”, the item relates to a pathology service when rendered by or on behalf of an approved pathology practitioner who is a recognised pathologist other than a pathology service:\n\n(a) rendered following a request made in the course of the provision of an out-patient service at a recognised hospital; or\n\n(b) rendered following a request made in respect of a person who was, at the time when the request was made, a private patient in a recognised hospital; or\n\n(c) in the rendering of which:\n\n(i) any pathology equipment of a recognised hospital, or a laboratory included in a prescribed class of laboratories, is used; or\n\n(ii) any member of the staff of a recognised hospital, or a laboratory included in a prescribed class of laboratories, participates in the course of that member’s employment with that hospital or laboratory.\n\n3. If an item includes the symbol “(OP)”, the item is taken to relate to a pathology service other than a pathology service:\n\n(a) to which an item that includes the symbol “(SP)” relates; or\n\n(b) to which subsection 16a (7) applies.\n\n4. For the purposes of rules 2 and 3, each of the following classes of laboratories is a prescribed class of laboratories:\n\n(a) laboratories operated by the Commonwealth;\n\n(b) laboratories operated by a State or an authority of a State;\n\n(c) laboratories operated by the Northern Territory;\n\n(d) laboratories operated by the Australian Capital Territory;\n\n \n\n(e) laboratories operated by an Australian tertiary education institution.\n\n5. 2 or more pathology services rendered following 2 or more requests are taken to have been rendered following a single request if:\n\n(a) each pathology service is rendered to the same person; and\n\n(b) each pathology service is listed in the same item; and\n\n(c) the determinations of the necessity for the pathology services were made on the same day.\n\n6. In rule 5, “service” includes an assay, estimation and test.\n\n7. A reference in these rules to a request made to an approved pathology practitioner includes a reference to a request that is taken for the purposes of section 16a, to have been made to that approved pathology practitioner.\n\n8. If:\n\n(a) a pathology service (in this rule called the “first pathology service”) is rendered following a request; and\n\n(b) an item of the table applies to that pathology service; and\n\n(c) another pathology service (in this rule called the “second pathology service”) is rendered following the request; and\n\n(d) the second pathology service is of a kind referred to in the item referred to in paragraph (b);\n\nthe second pathology service is treated as if it were subsumed within the first pathology service.\n\nExample: Dr Proctor requests an extended blood grouping test (covered by item 1192) and the test includes a basic blood grouping test (covered by item 1187). Item 1187 is referred to in item 1192. Benefit is payble under item 1192 for the extended blood grouping test but benefit is not payable separately under item 1187 for the basic blood grouping test.\n\n9. For the purposes of Division 1:\n\n(a) if pathology services of a kind referred to in item 1187, 1188, 1192 or 1193 are rendered to a person during a period of hospitalisation, the item applies only to the first pathology service of that kind rendered to the person during that person’s hospitalisation; and\n\n(b) tests performed on material stored from a previous patient episode (except tests specified in item 1198 of 1199) in response to a later request are treated as being part or that previous patient episode if the second request is made within 14 days of that previous patient episode.\n\n10. For the purposes of Division 2:\n\n(a) if a pathology service involving the measurement of any substance in urine requires a 24 hour urine collection or\n\n \ncalculation of a substance/creatinine ratio, that pathology service is treated as including any estimation of creatinine in other fluids necessary for calculation; and\n\n(b) tests performed on material stored from a previous patient episode in response to a subsequent request are treated as being part of that previous patient episode if the second request occurs within 14 days of that previous patient episode.\n\n11. For the purposes of Division 3:\n\n(a) serial examinations or cultures means examinations or cultures requested on the 1 occasion regardless of whether the materials are received on different days by the approved pathology practitioner and regardless of whether the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and\n\n(b) tests performed on material that has been stored from a previous patient episode in response to a later request are treated as being part of that previous patient episode if the further request occurs within 14 days of that previous patient episode.\n\n12. For the purposes of Division 4:\n\n(a) tests performed on material that has been stored from a previous patient episode in response to a later request are treated as being part of that previous patient episode if the further request occurs within 14 days of that previous patient episode; and\n\n(b) in items 2271, 2274, 2275, 2276, 2277, 2278, 2279 and 2280, the estimation of a single antibody includes qualitative and quantitative assays for that antibody.\n\n13. For the purposes of Division 5:\n\n(a) “biopsy material” means all tissue received by the approved pathology practitioner from any operation or group of operations performed on a patient at the same time other than a bone marrow biopsy; and\n\n(b) if a pathology service relating to the examination of biopsy material is rendered under an item set out in Division 5 in circumstances where a further pathology service specified in an item in Division 5 is rendered also in relation to that biopsy material all those pathology services are treated as 1 pathology service under the same item appropriate to the pathology services provided.\n\n14. For the purposes of Division 6, “serial examinations” means examinations requested on the same occasion regardless of whether the materials are received on different days by the approved pathology practitioner and regardless of whether the examinations were requested on 1 or more request forms by the treating practitioner.\n\n \n\n15. If in these Rules provision is made for 2 or more pathology services to be treated as 1 pathology service, a reference to an appropriate item is a reference to the item that incorporates whichever of the symbols “(SP)” or “(OP)” is relevant to the rendering of that pathology service.\n\n16. The lists of abbreviations at the end of the table are provided to allow users of the table to identify and refer to particular pathology services, or groups of pathology services, more accurately and efficiently.\n\nSERVICES AND FEES\n\n```html\n

Item

Pathology service

Fee

Division 1—Haematology

$

1163

Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, reticulocyte count—1 or 2 procedures (SP)

7.80

1164

Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, reticulocyte count—1 or 2 procedures (OP)

5.90

1168

3 or more procedures to which item 1163 applies, including any calculation or measurement of erythrocyte or other indices (SP)

10.60

1169

3 or more procedures to which item 1164 applies, including any calculation or measurement of erythrocyte or other indices (OP)

7.95

1170

Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and if performed, any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any services soecified in item 1419 (SP)

14.00

1171

Examination of blood film, with or without differential cell count, or differential cell count with or without examination of blood film, and if performed, any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, inlcuding any services soecified in item 1420 (OP)

10.45

1172

Full blood examination consisting of items 1168 and 1170 (SP)

24.50

Item

Pathology service

Fee

$

1173

Full blood examination consisting of items 1169 and 1171 (OP)

18.20

1176

Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by—erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine—1 or more procedures (SP)

32.00

1177

Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by—erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine—1 or more procedures (OP)

24.20

1179

Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and 2 of the following— examination for HbH, quantitation of HbA2 or HbF, including any service specified in item 1163, 1168, 1170 or 1172 (SP)

50.00

1180

Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and 2 of the following— examination for HbH, quantitation of HbA2 or HbF, including any service specified in item 1164, 1169, 1171 or 1173 (OP)

37.65

1181

Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immunochemical techniques, including any service specified in item 1163. 1168. 1170. 1172 or 1183 (SP)

154.00

1182

Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immunochemical techniques, including any service specified in item 1164, 1169, 1171, 1173 or 1184 (OP)

115.55

1183

Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any service specified in item 1163, 1168, 1170 or 1172 (SP)

112.00

1184

Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any service specified in item 1164, 1169, 1171 or 1173 (OP)

83.90

1187

Blood grouping, including back-grouping when performed—ABO and Rh (D antigen) (SP)

13.60

1188

Blood grouping, including back-grouping when performed—ABO and Rh (D antigen) (OP)

10.15

1192

Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—one or more systems, including any service specified in item 1187 (SP)

27.00

\n```\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------ |\n| | | $ |\n| 1193 | Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—one or more systems, including any service specified in item 1188 (OP) | 20.25 |\n| 1196 | Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any service specified in item 1163, 1168, 1170 or 1172 (SP) | 50.00 |\n| 1197 | Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any service specified in item 1164, 1169, 1171 or 1173 (OP) | 37.65 |\n| 1198 | Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any service specified in item 1163, 1168, 1170, 1172, 1187 or 1196 including all testing performed on any 1 day (SP) | 122.00 |\n| 1199 | Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any service specified in item 1164, 1169, 1171, 1173, 1188 or 1197 including all testing performed on any 1 day (OP) | 91.80 |\n| 1417 | Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any antibodies detected (SP) | 22.00 |\n| 1418 | Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any antibodies detected (OP) | 16.65 |\n| 1419 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) including service specified in item 1170 or 1172—1 or more tests (SP) | 12.20 |\n| 1420 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) including service specified in item 1171 or 1173—1 or more tests (OP) | 9.20 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | $ |\n| 1521 | Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of—fibrinogen degradation products, fibrin monomer or D-dimer—1 estimation (SP) | 16.80 |\n| 1522 | Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of—fibrinogen degradation products, fibrin monomer or D-dimer—1 estimation (OP) | 12.70 |\n| 1523 | 2 estimations specified in item 1521 (SP) | 22.00 |\n| 1524 | 2 estimations specified in item 1522 (OP) | 16.65 |\n| 1525 | 3 estimations specified in item 1521 (SP) | 28.00 |\n| 1526 | 3 estimations specified in item 1522 (OP) | 21.00 |\n| 1527 | 4 or more estimations specified in item 1521 (SP) | 33.00 |\n| 1528 | 4 or more estimations specified m item 1522 (OP) | 25.00 |\n| 1531 | Quantitative assay, by 1 or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus anticoagulant—1 estimation (SP) | 33.00 |\n| 1532 | Quantitative assay, by 1 or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus anticoagulant—1 estimation (OP) | 25.00 |\n| 1533 | 4 or more estimations specified in item 1531 (SP) | 106.00 |\n| 1534 | 4 or more estimations specified in item 1532 (OP) | 79.15 |\n| 1535 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—1 or more estimations (SP) | 66.00 |\n| 1538 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—1 or more estimations (OP) | 49.85 |\n| 1539 | Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin— 1 or more estimations (SP) | 44.50 |\n| 1540 | Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin— 1 or more estimations (OP) | 33.25 |\n| 1541 | Quantitative assay of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, Passovy factor— 1 estimation (SP) | 44.50 |\n| 1542 | Quantitative assay of Von Willebrand s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, Passovy factor— 1 estimation (OP) | 33.25 |\n| 1543 | 2 estimations as specified in item 1541 (SP) | 66.00 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 1544 | 2 estimations as specified in item 1542 (OP) | 49.85 |\n| 1550 | 3 or more estimations as specified in item 1541 (SP) | 83.00 |\n| 1551 | 3 or more estimations as specified in item 1542 (OP) | 62.55 |\n| | Division 2—Chemical Pathology | |\n| 1558 | Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of—alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 1734), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea—1 estimation (SP) | 14.00 |\n| 1559 | Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of—alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 1735), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea—1 estimation (OP) | 10.45 |\n| 1560 | 2 estimations specified in item 1558 (SP) | 16.80 |\n| 1561 | 2 estimations specified in item 1559 (OP) | 12.70 |\n| 1562 | 3 estimations specified in item 1558 (SP) | 19.60 |\n| 1563 | 3 estimations specified in item 1559 (OP) | 14.75 |\n| 1564 | 4 estimations specified in item 1558 (SP) | 22.00 |\n| 1565 | 4 estimations specified in item 1559 (OP) | 16.65 |\n| 1569 | 5 estimations specified in item 1558 (SP) | 25.00 |\n| 1570 | 5 estimations specified in item 1559 (OP) | 18.65 |\n| 1571 | 6 or more estimations specified in item 1558 (SP) | 28.00 |\n| 1572 | 6 or more estimations specified in item 1559 (OP) | 21.00 |\n| 1575 | Qualitative estimation by any method, except by reagent strip or dip-stick of the following urine constituents— bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma—1 or more estimations (SP) | 13.20 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 1576 | Qualitative estimation by any method, except by reagent strip or dip-stick of the following urine constituents— bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma—1 or more estimations (OP) | 10.00 |\n| 1577 | Qualitative estimation by any method except by reagent strip or dip-stick of the following faecal constituents— haemoglobin, porphyrins, reducing substances—each estimation, to a maximum of 3 estimations, taken on separate days (SP) | 8.90 |\n| 1578 | Qualitative estimation by any method except by reagent strip or dip-stick of the following faecal constituents— haemoglobin, porphyrins, reducing substances—each estimation, to a maximum of 3 estimations, taken on separate days (OP) | 6.65 |\n| 1579 | Immunological tests for human haemoglobin in faeces performed in any 28 day period, including chemical test if performed—1 estimation (SP) | 16.80 |\n| 1580 | Immunological tests for human haemoglobin in faeces performed in any 28 day period, including chemical test if performed—1 estimation (OP) | 12.70 |\n| 1581 | 2 or more estimations specified in item 1579 (SP) | 38.50 |\n| 1582 | 2 or more estimations specified in item 1580 (OP) | 28.95 |\n| 1583 | Osmolality, estimation by osmometer, in serum or in urine—1 or more estimations (SP) | 33.00 |\n| 1584 | Osmolality, estimation by osmometer, in serum or in urine—1 or more estimations (OP) | 25.00 |\n| 1590 | Quantitative estimation of blood gases including tests performed from—pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (e.g. haemoglobin, potassium) or calculation performed on the same specimen—1 or more estimation on 1 specimen (SP) | 45.50 |\n| 1591 | Quantitative estimation of blood gases including tests performed from—pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (e.g. haemoglobin, potassium) or calculation performed on the same specimen—1 or more estimation on 1 specimen (OP) | 34.05 |\n| 1592 | 1 or more estimations of blood gases as specified in item 1590 on 2 or more specimens within any 1 day (SP) | 56.00 |\n| 1593 | 1 or more estimations of blood gases as specified in item 1591 on 2 or more specimens within any 1 day (OP) | 41.95 |\n| 1595 | Calculus, analysis of 1 or more (SP) | 41.00 |\n| 1596 | Calculus, analysis of 1 or more (OP) | 30.90 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 1598 | Drug or chemical assays—including all qualitative and quantitative tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any service specified in item 1712, 1714 or 1716, but excluding the surveillance of sports people and athletes for performance improving substances—1 or more assays (SP) | 56.00 |\n| 1599 | Drug or chemical assays—including all qualitative and quantitative tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any service specified in item 1713, 1715 or 1717, but excluding the surveillance of sports people and athletes for performance improving substances—1 or more assays (OP) | 41.95 |\n| 1627 | Drug assays—including all qualitative and quantitative estimations on blood, urine or other body fluid for a drug of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programmes—each assay to a maximum of 4 assays within any 28 day period (SP) | 28.00 |\n| 1628 | Drug assays—including all qualitative and quantitative estimations on blood, urine or other body fluid for a drug of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programmes—each assay to a maximum of 4 assays within any 28 day period (OP) | 21.00 |\n| 1712 | Drug assay—quantitative estimation on blood or other body fluid by any method of a drug being used therapeutically for the patient from whom the specimen was taken and not elsewhere specified in the Schedule— 1 estimation (SP) | 28.00 |\n| 1713 | Drug assay—quantitative estimation on blood or other body fluid by any method of a drug being used therapeutically for the patient from whom the specimen was taken and not elsewhere specified in the Schedule— 1 estimation (OP) | 21.00 |\n| 1714 | 2 estimations specified in item 1712 (SP) | 38.50 |\n| 1715 | 2 estimations specified in item 1713 (OP) | 28.95 |\n| 1716 | 3 or more estimations specified in item 1712 (SP) | 50.00 |\n| 1717 | 3 or more estimations specified in item 1713 (OP) | 37.65 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ----- |\n| | | $ |\n| 1726 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid— 1 or more examinations or estimations (SP) | 44.50 |\n| 1727 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid— 1 or more examinations or estimations (OP) | 33.25 |\n| 1734 | Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase or lipoprotein electrophoresis (only when the Cholesterol is >6.5mmol/l and Triglyceride >3.0 mmol/1 or in the diagnosis of types III and IV hyperlipidemia), including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity—1 examination to a maximum of 2 examinations in any 12 month period (SP) | 41.00 |\n| 1735 | Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase or lipoprotein electrophoresis (only when the Cholesterol is >6.5 mmol/1 and Triglyceride >3.0 mmol/1 or in the diagnosis of types III and IV hyperlipidemia), including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity—1 examination to a maximum of 2 examinations in any 12 month period (OP) | 30.90 |\n| 1736 | Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a 28 day period, serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, including the preliminary quantitation of total protein, albumin and globulin, or of total relevant enzyme activity—2 or more examinations (SP) | 61.00 |\n| 1737 | Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a 28 day period, serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, including the preliminary quantitation of total protein, albumin and globulin, or of total relevant enzyme activity—2 or more examinations (OP) | 45.90 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 1738 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1752), Haptoglobins, Microalbumin (in proven diabetes mellitus), Prealbumin, Prostate Specific Antigen, Prostatic Acid Phosphatase, Transferrin (unless specified in item 1752) and, in the follow-up of proven malignancy, Mucin-like carcinoma associated antigen, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, SCC Related antigen, Thyroglobulin—quantitative estimation in serum, urine or other body fluid—1 estimation (SP) | 27.00 |\n| 1739 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 1753), Haptoglobins, Microalbumin (in proven diabetes mellitus), Prealbumin, Prostate Specific Antigen, Prostatic Acid Phosphatase, Transferrin (unless specified in item 1753) and, in the follow up of proven malignancy, Mucin-like carcinoma associated antigen, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, SCC Related antigen, Thyroglobulin—quantitative estimation in serum, urine or other body fluid—1 estimation (OP) | 20.25 |\n| 1740 | 2 or more estimations specified in item 1738 (SP) | 50.00 |\n| 1741 | 2 or more estimations specified in item 1739 (OP) | 37.65 |\n| 1752 | Iron studies consisting of quantitative analysis of iron, | 53.00 |\n| 1753 | transferrin or iron binding capacity and ferritin (SP) Iron studies consisting of quantitative analysis of iron, transferrin or iron binding capacity and ferritin (OP) | 39.60 |\n| 1768 | Serum B12, serum folate—1 or more estimations within any 28 day period (SP) | 33.00 |\n| 1769 | Serum B12, serum folate—1 or more estimations within any 28 day period (OP) | 25.00 |\n| 1770 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of 3 estimations in any 12 month period (SP) | 61 00 |\n| 1771 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of 3 estimations in any 12 month period (OP) | 45.40 |\n| 1780 | Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, B1, B2, B3, B6, C, and E—1 or more estimations within any 6 month period (SP) | 41.00 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 1783 | Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, B1, B2, B3, B6, C, and E—1 or more estimations within any 6 month period (OP) | 30.90 |\n| 1786 | Vitamin D or D fractions—1 or more estimations (SP) | 41.00 |\n| 1787 | Vitamin D or D fractions—1 or more estimations (OP) | 30.90 |\n| 1791 | Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (1 or more fractions), oxalate, pyruvate, serotonin, xylose, zinc—1 quantitative estimation (SP) | 33.00 |\n| 1792 | Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (1 or more fractions), oxalate, pyruvate, serotonin, xylose, zinc—1 quantitative estimation (OP) | 25.00 |\n| 1795 | 2 or more estimations specified in item 1791 (SP) | 52.00 |\n| 1798 | 2 or more estimations specified in item 1792 (OP) | 39.20 |\n| 1871 | Aluminium, arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium—in blood, urine or other body fluid or tissue—1 or more estimations within any 6 month period (SP) | 47.00 |\n| 1872 | Aluminium, arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium—in blood, urine or other body fluid or tissue—1 or more estimations within any 6 month period (OP) | 35.25 |\n| 1895 | Blood lead estimation, other than for occupational health screening purposes, to a maximum of 3 estimations in any 6 month period—each estimation (SP) | 41.00 |\n| 1896 | Blood lead estimation, other than for occupational health screening purposes, to a maximum of 3 estimations in any 6 month period—each estimation (OP) | 30.90 |\n| 1959 | Porphyrins (1 or more fractions), Catecholamines (1 or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA)—quantitative including any qualitative estimations—1 or more estimations (SP) | 54.00 |\n| 1960 | Porphyrins (1 or more fractions), Catecholamines (1 or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA)—quantitative including any qualitative estimations—1 or more estimations (OP) | 40.40 |\n| 1963 | Faecal fat, Breath Hydrogen measurements m response to loading with disaccharides—1 or more quantitative estimations within any 28 day period (SP) | 54.00 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | $ |\n| 1964 | Faecal fat, Breath Hydrogen measurements in response to loading with disaccharides—1 or more quantitative estimations within any 28 day period (OP) | 40.40 |\n| 1969 | Solid tissue or tissues excluding blood elements—assay of 1 or 2 enzymes (SP) | 54.00 |\n| 1970 | Solid tissue or tissues excluding blood elements—assay of 1 or 2 enzymes (OP) | 40.40 |\n| 1975 | Assay of 3 to 5 enzymes as specified in item 1969 (SP) | 100.00 |\n| 1976 | Assay of 3 to 5 enzymes as specified in item 1970 (OP) | 75.20 |\n| 1977 | Assay of 6 or more enzymes as specified in item 1969 (SP) | 132.00 |\n| 1978 | Assay of 6 or more enzymes as specified in item 1970 (OP) | 99.70 |\n| 1983 | Thyroid function tests, including thyrotrophin (TSH) and at least 1 or more of the following tests—free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin (SP) | 56.00 |\n| 1984 | Thyroid function tests, including thyrotrophin (TSH) and at least 1 or more of the following tests—free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin (OP) | 41.95 |\n| 1985 | Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones (SP) | 66.00 |\n| 1986 | Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones (OP) | 49.85 |\n| 1989 | Growth hormone suppression by glucose loading, Growth hormone stimulation by exercise, Dexamethasone suppression test, L-Dopa stimulation of growth hormone, where physically performed by a recognised pathologist—1 or more procedures (SP) | 15.80 |\n| 1990 | Growth hormone suppression by glucose loading, Growth hormone stimulation by exercise, Dexamethasone suppression test, L-Dopa stimulation of growth hormone, where physically performed by a recognised pathologist—1 or more procedures (OP) | 11.90 |\n| 1991 | Gonadotrophin releasing hormone stimulation test, Synacthen stimulation test, Glucagon stimulation test with C-peptide measurement, Pentagastrin stimulation of thyrocalcitonin release, Secretin stimulation of gastrin release, Insulin hypoglycaemia, Arginine infusion, where physically performed by a recognised pathologist—1 procedure (SP) | 53.00 |\n| 1992 | Gonadotrophin releasing hormone stimulation test, Synacthen stimulation test, Glucagon stimulation test with C-peptide measurement, Pentagastrin stimulation of thyrocalcitonin release, Secretin stimulation of gastrin release, Insulin hypoglycaemia, Arginine infusion, where physically performed by a recognised pathologist—1 procedure (OP) | 39.60 |\n| 1993 | 2 or more tests specified in item 1991 (SP) | 84.00 |\n| 1994 | 2 or more tests specified in item 1992 (OP) | 63.30 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | $ |\n| 2021 | Hormones and hormone binding proteins, quantitative estimation by any method of: ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth hormone, Human Placental Lactogen, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti-diuretic hormone)—1 estimation (SP) | 38.50 |\n| 2024 | Hormones and hormone binding proteins, quantitative estimation by any method of: ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth hormone, Human Placental Lactogen, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti-diuretic hormone)—1 estimation (OP) | 28.95 |\n| 2025 | 2 estimations specified in item 2021 (SP) | 61.00 |\n| 2026 | 2 estimations specified in item 2024 (OP) | 45.90 |\n| 2027 | 3 estimations specified in item 2021 (SP) | 77.00 |\n| 2028 | 3 estimations specified in item 2024 (OP) | 57.80 |\n| 2029 | 4 estimations specified in item 2021 (SP) | 94.00 |\n| 2030 | 4 estimations specified in item 2024 (OP) | 70.45 |\n| 2031 | 5 estimations specified in item 2021 (SP) | 106.00 |\n| 2032 | 5 estimations specified in item 2024 (OP) | 79.15 |\n| 2033 | 6 or more estimations specified in item 2021 (SP) | 118.00 |\n| 2034 | 6 or more estimations specified in item 2024 (OP) | 88.65 |\n| 2037 | Hormone receptor assay on proven primary breast carcinoma or subsequent lesion in the breast or metastasis from a breast carcinoma—1 or more assays (SP) | 108.00 |\n| 2038 | Hormone receptor assay on proven primary breast carcinoma or subsequent lesion in the breast or metastasis from a breast carcinoma—1 or more assays (OP) | 80.75 |\n| 2039 | HDL Cholesterol, estimation of, in patients with serum cholesterol >5.5mmol/l or those on prescribed lipid lowering drugs—each estimation to a maximum of 4 estimations in any 12 month period (SP) | 16.80 |\n| 2040 | HDL cholesterol, estimation of, in patients with serum cholesterol >5.5mmol/l or those on prescribed lipid lowering drugs—each estimation to a maximum of 4 estimations in any 12 month period (OP) | 12.70 |\n\n \n\n```html\n

Item

Pathology service

Fee

$

2043

Glycosylated haemoglobin only when performed in the management of established diabetes—each estimation to a maximum of 4 estimations in any 12 month period (SP)

22.50

2044

Glycosylated haemoglobin only when performed in the management of established diabetes—each estimation to a maximum of 4 estimations in any 12 month period (OP)

17.05

Division 3—Microbiology

2083

Microscopic examination of material other than blood, from 1 or more sites, obtained directly from a patient and excluding material from cultures—wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparations using any relevant stain or stains—1 or more examinations (SP)

10.00

2084

Microscopic examination of material other than blood, from 1 or more sites, obtained directly from a patient and excluding material from cultures—wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparations using any relevant stain or stains—1 or more examinations (OP)

7.55

2085

Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of 3 estimations taken on separate days including any service specified in item 2083—each estimation (SP)

16.80

2086

Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of 3 estimations taken on separate days including any service specified in item 2084—each estimation (OP)

12.70

2087

The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083—1 or more sites (SP)

26.50

2088

The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084—1 or more sites (OP)

19.80

\n```\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 2089 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic microorganisms, including fungi but excluding viruses, from the following sites—skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens), or specimens of sputum (except when part of item 2119), including pathogenic identification and antibiotic sensitivity testing, including any service specified in item 2083 or 2087—1 or more examinations on 1 or more specimens (SP) | 38.50 |\n| 2090 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic microorganisms, including fungi but excluding viruses, from the following sites: skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens), or specimens of sputum (except where part of item 2120), including pathogenic identification and antibiotic sensitivity testing, including any service specified in item 2084 or 2088—1 or more examinations on 1 or more specimens (OP) | 28.95 |\n| 2098 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic microorganisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083, 2087 or 2089—1 or more sites (SP) | 52.00 |\n| 2099 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic microorganisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084, 2088 or 2090—1 or more sites (OP) | 39.20 |\n| 2117 | Cultural examination (including the detection of Clostridial toxins or antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least 2 selective or enrichment media as well as culture in at least 2 different atmospheres and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2083, to a maximum of 3 specimens in any 7 day period—each examination (SP) | 63.00 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 2118 | Cultural examination (including the detection of Clostridial toxins or antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least 2 selective or enrichment media as well as culture in at least 2 different atmospheres and including pathogen identification and antibiotic sensitivity testing, including any service specified in item 2084, to a maximum of 3 specimens in any 7 day period—each examination (OP) | 47.50 |\n| 2119 | Microscopy with appropriate stains and cultural examinations of 3 specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any service specified in item 2083 (SP) | 89.00 |\n| 2120 | Microscopy with appropriate stains and cultural examinations of 3 specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any service specified in item 2084 (OP) | 66.50 |\n| 2123 | Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and sub-cultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing-each set of cultures to a maximum of 3 sets (SP) | 23.00 |\n| 2124 | Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and sub-cultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing-each set of cultures to a maximum of 3 sets (OP) | 17.45 |\n| 2127 | Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts. (Simple culture by dip slide is excluded from this item) (SP) | 28.00 |\n| 2128 | Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts. (Simple culture by dip slide is excluded from this item) (OP) | 21.00 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 2129 | Direct detection of the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varicella zoster or detection of Clostridium difficile toxin except where item 2117 has been performed—1 or more estimations (SP) | 22.00 |\n| 2130 | Direct detection of the antigens of Heamophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varcella zoster or detection of Clostridium difficile toxin except where item 2118 has been performed—1 or more estimations (OP) | 16.65 |\n| 2133 | Direct detection of Chlamydia from clinical material, not cultures—1 or more estimations (SP) | 13.20 |\n| 2134 | Direct detection of Chlamydia from clinical material, not cultures—1 or more estimations (OP) | 10.00 |\n| 2135 | Direct detection of Herpes simplex from clinical material, not cultures—1 or more estimations (SP) | 13.20 |\n| 2136 | Direct detection of Herpes simplex from clinical material, not cultures—1 or more estimations (OP) | 10.00 |\n| 2139 | Investigation for Herpes simplex virus (1 or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by 1 or more cultural methods, including any service specified in item 2133 or 2135 (SP) | 38.50 |\n| 2140 | Investigation for Herpes simplex virus (1 or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by 1 or more cultural methods, including any service specified in item 2134 or 2136 (OP) | 28.95 |\n| 2145 | Serology including IgG and IgM estimations of Rubella, toxoplasma or CMV when performed during pregnancy—1 or more assays (SP) | 18.80 |\n| 2146 | Serology including IgG and IgM estimations of Rubella, toxoplasma or CMV when performed during pregnancy—1 or more assays (SP) | 14 10 |\n| 2181 | Antibodies to microbial or exogenous antigens not elsewhere specified in the Schedule—estimation of 1 antibody (SP) | 18.80 |\n| 2182 | Antibodies to microbial or exogenous antigens not elsewhere specified in the Schedule—estimation of 1 antibody (OP) | 14.10 |\n| 2183 | 2 estimations specified in item 2181 (SP) | 29.00 |\n| 2184 | 2 estimations specified in item 2182 (OP) | 21.80 |\n| 2185 | 3 estimations specified in item 2181 (SP) | 38.50 |\n| 2186 | 3 estimations specified in item 2182 (OP) | 28.95 |\n| 2187 | 4 estimations specified in item 2181 (SP) | 48.50 |\n| 2188 | 4 estimations specified in item 2182 (OP) | 36.40 |\n| 2189 | 5 estimations specified in item 2181 (SP) | 59.00 |\n| 2190 | 5 estimations specified in item 2182 (OP) | 44.35 |\n| 2191 | 6 or more estimations specified in item 2181 (SP) | 69.00 |\n| 2192 | 6 or more estimations specified in item 2182 (OP) | 51.45 |\n| 2221 | Hepatitis B surface antigen test (SP) | 18.80 |\n\n \n\n```html\n

Item

Pathology service

Fee

$

2222

Hepatitis B surface antigen test (OP)

14.10

2223

Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including service specified in item 2221, 2229 or 2231 (SP)

25.35

2224

Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including service specified in item 2222, 2230 or 2232 (OP)

19.00

2229

All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those service specified in item 2221, 2223 or 2231 (SP)

50.15

2230

All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those services specified in item 2222, 2224 or 2232 (OP)

37.65

2231

All tests performed in the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen or Hepatitis B surface antibody tests, including services specified in item 2221 or 2223 (SP)

36.40

2232

All tests performed m the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen or Hepatitis B surface antibody tests, including services specified in item 2222 or 2224 (OP)

27.35

2235

Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent—1 or more estimations (SP)

33.25

2236

Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent—1 or more estimations (OP)

25.00

Division 4—Immunology

2239

Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1734, 1736 or 2245), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresis or immunofixation—1 or more procedures (SP)

41.15

2240

Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1735, 1737 or 2246), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresis or immunofixation—1 or more procedures (OP)

30.90

\n```\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 2241 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1734, 1736 or 2245) on serum and urine concurrently collected—2 or more procedures (SP) | 61.20 |\n| 2242 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 1735, 1737 or 2246) on serum and urine concurrently collected—2 or more procedures (OP) | 45.90 |\n| 2245 | Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method— estimation of 1 immunoglobin (SP) | 20.05 |\n| 2246 | Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method— estimation of 1 immunoglobin (OP) | 15.05 |\n| 2251 | 2 estimations specified in item 2245 (SP) | 31.15 |\n| 2252 | 2 estimations specified in item 2246 (OP) | 23.40 |\n| 2253 | 3 or more estimations specified in item 2245 (SP) | 42.20 |\n| ??54 | 3 or more estimations specified in item 2246 (OP) | 31.65 |\n| 2255 | Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or IgA—1 or more estimation (SP) | 61.20 |\n| 2256 | Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or IgA—1 or more estimation (OP) | 45.90 |\n| 2257 | Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of 2 estimations in any 12 month period (SP) | 35.35 |\n| 2258 | Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of 2 estimations in any 12 month period (OP) | 26.60 |\n| 2259 | Specific IgG or IgE antibodies to potential allergens—1 or more tests for single or multiple allergens with a maximum of 4 estimations in any 12 month period (SP) | 32.20 |\n| 2260 | Specific IgG or IgE antibodies to potential allergens—1 or more tests for single or multiple allergens with a maximum of 4 estimations in any 12 month period (OP) | 24.20 |\n| 2261 | Antinuclear antibodies, detection in serum or other body fluids, including quantitation if required (SP) | 33.25 |\n| 2262 | Antinuclear antibodies, detection in serum or other body fluids, including quantitation if required (OP) | 25.00 |\n| 2263 | Measurment of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method), performed only where a positive antinuclear antibody titre of 1:40 or greater has been obtained (SP) | 40.65 |\n| 2266 | Measurement of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method), performed only where a positive antinuclear antibody titre of 1:40 or greater has been obtained (OP) | 30.45 |\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ----- |\n| | | $ |\n| 2267 | Antibodies to extractable nuclear antigens, detection of in serum or other body fluids (SP) | 28.00 |\n| 2268 | Antibodies to extractable nuclear antigens, detection of in serum or other body fluids (OP) | 21.00 |\n| 2269 | Characterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including services specified in item 2267 (SP) | 44.35 |\n| 2270 | Charaterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including services specified in item 2268 (OP) | 33.25 |\n| 2271 | Antibodies to tissue antigens that are not elsewhere specified in an item in the Schedule—estimation of 1 antibody (SP) | 33.25 |\n| 2274 | Antibodies to tissue antigens which are not elsewhere specified in an item in the Schedule—estimation of 1 antibody (OP) | 25.00 |\n| 2275 | 2 estimations specified in item 2271 (SP) | 38.55 |\n| 2276 | 2 estimations specified in item 2274 (OP) | 28.95 |\n| 2277 | 3 estimations specified in item 2271 (SP) | 44.35 |\n| 2278 | 3 estimations specified in item 2274 (OP) | 33.25 |\n| 2279 | 4 or more estimations specified in item 2271 (SP) | 50.15 |\n| 2280 | 4 or more estimations specified in item 2274 (OP) | 37.65 |\n| 2281 | Rheumatoid factor, detection of by any technique (SP) | 13.30 |\n| 2282 | Rheumatoid factor, detection of by any technique (OP) | 10.00 |\n| 2283 | Quantitation of Rheumatoid factor where detected, including services specified in item 2281 (SP) | 26.40 |\n| 2284 | Quantitation of Rheumatoid factor where detected, including services specified in item 2282 (OP) | 19.80 |\n| 2289 | Complement—total and components—1 quantitative estimation (SP) | 22.20 |\n| 2290 | Complement—total and components—1 quantitative estimation (OP) | 16.65 |\n| 2291 | 2 estimations as specified in item 2289 (SP) | 33.25 |\n| 2292 | 2 estimations as specified in item 2290 (OP) | 25.00 |\n| 2293 | 3 or more estimations as specified in item 2289 (SP) | 44.35 |\n| 2312 | 3 or more estimations as specified in item 2290 (OP) | 33.25 |\n| 2313 | Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function tests (SP) | 41.15 |\n| 2314 | Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function tests (OP) | 30.90 |\n| 2315 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Division 1 — Haematology in the Schedule (SP) | 69.65 |\n| 2316 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Division 1 — Haematology in the Schedule (OP) | 52.25 |\n| 2317 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques to assess lymphoid populations using a minimum of 3 monoclonal antibodies, including any services in item 2319—1 or more estimations (SP) | 88.65 |\n\n \n\n```html\n

Item

Pathology service

Fee

$

2318

Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques to assess lymphoid populations using a minimum of 3 monoclonal antibodies, including any service in item 2320—1 or more estimations (OP)

66.50

2319

Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques in the investigation of a probable haematological malignancy using a minimum of 7 monoclonal antibodies, including any services in item 2317—1 or more estimations (SP)

211.00

2320

Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniques in the investigation of a probable haematological malignancy using a minimum of 7 monoclonal antibodies, including any service in item 2318—1 or more estimations (OP)

158.25

2321

HLA typing comprising A. B. C and DR phenotypes (SP)

93.90

2322

HLA typing comprising A, B, C and DR phenotypes (OP)

70.45

2323

HLA typing, excluding any service specified in item 2321— 1 or more antigens (SP)

38.55

2324

HLA typing, excluding any service specified in item 2322— 1 or more antigens (OP)

28.95

2325

Mantoux test (SP)

13.30

2326

Mantoux test (OP)

10.00

Division 5—Histopathology

2327

Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions (SP)

93.90

2328

Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions (OP)

70.45

2329

Immediate frozen section diagnosis of biopsy material, including any other histopathology examination (SP)

175.15

2330

Immediate frozen section diagnosis of biopsy material, including any other histopathology examination (OP)

131.35

2331

Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any other histopathology examination (SP)

132.95

2332

Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any other histopathology examination (OP)

99.70

2333

Electron microscopy of biopsy material including any other histopathology examination (SP)

141.40

2337

Electron microscopy of biopsy material including any other histopathology examination (OP)

106.05

Division 6—Cytopathology

2338

Cytological examination of smears from cervix or vagina for detection of pre-cancerous or cancerous changes— 1 or more examinations (SP)

20.50

\n```\n\n \n\n```html\n

Item

Pathology service

Fee

$

2339

Cytological examination of smears from cervix or vagina for detection of pre-cancerous or cancerous changes— 1 or more examinations (OP)

15.40

2340

Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of pre-cancerous or cancerous changes—1 or more examinations (SP)

20.50

2341

Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of pre-cancerous or cancerous changes—1 or more examinations (OP)

15.40

2343

Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 2340 and any histopathological service performed on that cytology specimen—1 or more examinations (SP)

40.10

2344

Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 2341 and any histopathological service performed on that cytology specimen—1 or more examinations (OP)

30.10

2348

Cytological examination including examination of a series of 3 sputum or urine specimens for malignant cells (SP)

83.35

2349

Cytological examination including examination of a series of 3 sputum or urine specimens for malignant cells (OP)

62.55

2350

Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues (SP)

50.15

2351

Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues (OP)

37.65

2355

Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance (SP)

93.90

2356

Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance (OP)

70.45

Division 7—Cytogenetics

2360

Chromosome studies, including preparation, count and karyotyping of 1 or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood—1 or more estimations (SP)

181.50

\n```\n\n \n\n```html\n

Item

Pathology service

Fee

$

2361

Chromosome studies, including preparation, count and karyotyping of 1 or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood—1 or more estimations (OP)

136.10

2363

Chromosome studies, including preparation, count and karyotyping of blood (SP)

164.60

2364

Chromosome studies, including preparation, count and karyotyping of blood (OP)

123.45

2365

Chromosome identification by banding techniques (using fluorescein, Giemsa, or centromere staining or high resolution analysis) or by fragile X-site determination— 1 or more identifications (SP)

141.40

2366

Chromosome identification by banding techniques (using fluorescein, Giemsa, or centromere staining or high resolution analysis) or by fragile X-site determination— 1 or more identifications (OP)

106.05

Division 8—Infertility and Pregnancy Tests

2370

Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test) (SP)

9.30

2371

Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test) (OP)

7.00

2372

Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and 1 or more chemical tests, with a maximum of 4 examinations in any 12 month period (SP)

38.55

2373

Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and 1 or more chemical tests, with a maximum of 4 examinations in any 12 month period (OP)

28.95

2377

Sperm antibodies, sperm penetrating ability—1 or more tests (SP)

24.80

2378

Sperm antibodies, sperm penetrating ability—1 or more tests (OP)

18.65

2379

Chorionic gonadotrophin (beta—HCG), qualitative estimation in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of

pregnancy—1 or more estimations (SP)

13.55

2380

Chorionic gonadotrophin (beta—HCG), qualitative estimation in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy—1 or more estimations (OP)

10.15

2384

Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG—secreting neoplasm, threatened abortion or follow-up of abortion (SP)

38.55

\n```\n\n \n\n| Item | Pathology service | Fee |\n| ---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----- |\n| | | $ |\n| 2385 | Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG—secreting neoplasm, threatened abortion or follow-up of abortion (OP) | 28.95 |\n| | Division 9—Simple Basic Pathology Tests | |\n| 2387 | Seminal examination for presence of spermatozoa | 6.20 |\n| 2389 | Blood count consisting of leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count) or any or all of haemoglobin estimation, haematocrit estimation or erythrocyte count—1 procedure | 4.15 |\n| 2390 | 2 procedures specified in item 2389 | 6.20 |\n| 2391 | 3 or more procedures specified in item 2389 | 8.25 |\n| 2393 | Microscopical examination of urine | 4.15 |\n| 2394 | Pregnancy test by 1 or more immunochemical methods | 10.15 |\n| 2395 | Microscopical examination of wet film other than urine | 6.20 |\n| 2396 | Microscopical examination of gram-stained film | 7.85 |\n| 2397 | Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method | 2.10 |\n| 2398 | Microscopical examination screening for fungi in skin, hair or nails—1 or more sites | 6.20 |\n| 2399 | Mantoux test | 10.15 |\n\n \nABBREVIATIONS\n\nA. ABBREVIATIONS FOR GROUPS OF TESTS\n\n| Group | Estimationsincluded in group | Abbreviation | Itemnumbers |\n| -------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------ | ----------- |\n| Cardiac Enzymes | Lactate dehydrogenase (LDH) Aspartate aminotransferase (AST) andCreatine kinase (CK) | CE | 1562, 1563 |\n| Coagulation Studies | Prothrombin Time, activated partial thromboplastin time and 2 or more of the following tests: bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer, Factor XIII screening tests. | COAG | 1527, 1528 |\n| Electrolytes | Sodium (NA), Potassium (K), Chloride (CL) and Bicarbonate (HC03) | E | 1564, 1565 |\n| Lipid Studies | Cholesterol (CHOL) and Triglycerides (TRIG) | FATS | 1560, 1561 |\n| Liver Function Tests | Alkaline phosphatase (ALP), Alanine aminotransferase (ALT),Aspartate aminotransferase (AST)Albumin (ALB), Bilirubin (BIL), Gamma glutamyl transpeptidase (GGT), Lactate dehydrogenase (LDH) and Protein (PROT) | LFT | 1571, 1572 |\n| Syphilis Serology | Rapid plasma reagin test (RPR) or venereal disease research laboratory test (VDRL) and Treponema pallidum haemagglutin test (TPHA) or Fluorescent Treponemal antibody-absorption test (FTA) | STS | 2183, 2184 |\n\n \n\nB. ABBREVIATIONS FOR INDIVIDUAL TESTS\n\nThe abbreviations are listed alphabetically within the following Divisions:\n\n1\\. HAEMATOLOGY\n\n2\\. CHEMICAL PATHOLOGY\n\n3\\. MICROBIOLOGY\n\n4\\. IMMUNOLOGY\n\n5\\. HISTOPATHOLOGY\n\n6\\. CYTOPATHOLOGY\n\n7\\. CYTOGENETICS\n\n8\\. INFERTILITY AND PREGNANCY TESTS\n\n```html\n

Approved item name of test in Schedule

Abbreviation

Item numbers

DIVISION 1—HAEMATOLOGY

Antithrombin III

ATH

1531, 1532

Abnormal haemoglobins—spectroscopic examination of blood

AH

1419, 1420

Bleeding Time

BT

1521, 1522

Blood coagulation factors—quantitative assays:

Von Willebrand’s factor antigen

VWA

1541, 1542

Von Willebrand’s factor

VWF

1541, 1542

Fletcher Factor

FF

1541, 1542

Fitzgerald Factor

FGF

1541, 1542

Passovy Factor

PF

1541, 1542

Factor II

FII

1541, 1542

Factor V

FV

1541, 1542

Factor VII

FVII

1541, 1542

Factor VIII

FVIII

1541, 1542

Factor IX

FIX

1541, 1542

Factor X

FX

1541, 1542

Factor XI

FXI

1541, 1542

Factor XII

FXII

1541, 1542

Factor XIII

XIII

1541, 1542

Blood Film

BF

1170, 1171

Blood Group Antibodies

BGA

1417, 1418

Blood Grouping—ABO and Rh (D antigen)

BG

1187, 1188

Blood Group and blood group antibodies (group and hold)

BGAB

1196, 1197

Blood Group Systems (Duffy, Kell, M & N factors, Rh phenotypes)

BGS

1192, 1193

Bone Marrow Examination—Trephine

BMET

1181, 1182

Bone Marrow Examination—Aspirate

BMEA

1183, 1184

Carboxyhaemaglobin

COHB

1419, 1420

Coagulation Time

CT

1521, 1522

Cold Agglutinins

CAG

1419, 1420

Compatibility testing

XMAT

1198, 1199

C-reactive protein

CRP

1163, 1164

Differential Cell Count

DIFF

1170, 1171

Direct Coombs test

CMBS

1419, 1420

D-dimer test

DD

1521, 1522

Erythrocyte Count

RCC

1163, 1164

Erythrocyte Metabolic Enzymes

ERYM

1176, 1177

Erythrocyte Sedimentation Rate

ESR

1163, 1164

Erythrocyte Haemolysis

ERYH

1176, 1177

Euglobulin clot lysis time

ECLT

1531, 1532

Fibrinogen Degradation Products

FDP

1521, 1522

Approved item name of test in Schedule

Abbreviation

Item numbers

Fibrin Monomer

FM

1521, 1522

Fibrinogen

FIB

1521, 1522

Full Blood Examination

FBE

1172, 1173

Haematocrit

HCT

1163, 1164

Haemoglobin Estimation

HB

1163, 1164

Haemoglobinopathy tests

HMGP

1179, 1180

Heparin Cofactor II

HRNC

1531, 1532

Heparin Estimation

HEPR

1539, 1540

Heterophile Antibodies (Infectious Mononucleosis Test)

IM

1419, 1420

Leucocyte Count

WCC

1163, 1164

Lupus Anticoagulant

LUPA

1531, 1532

Metalbumin detection (Schumm’s test)

SCHM

1419, 1420

Plasminogen

PLAS

1531, 1532

Partial Thromboplastin Time

PTT

1521, 1522

Platelet Aggregation

PLTG

1535, 1538

Platelet Count

PLTC

1163, 1164

Protein C

PROC

1531, 1532

Protein S

PROS

1531, 1532

Prothrombin Time

PT

1521, 1522

Red Cell Porphyrins—qualitative test

RCP

1419, 1420

Reticulocyte Count

RETC

1163, 1164

Test for Factor XIII Deficiency

F13D

1521, 1522

Thalassaemia Studies

TS

1179, 1180

Thrombin Time

TT

1521, 1522

Viscosity of blood or plasma

VISC

1163, 1164

DIVISION 2—CHEMICAL PATHOLOGY

Acetoacetate

ACAT

1791, 1792

Alanine Aminotransferase

ALT

1558, 1559

Albumin

ALB

1558, 1559

Alcohol (Ethanol)

ETOH

1791, 1792

Alkaline Phosphatase

ALP

1558, 1559

Alkaline Phosphatase Isoenzymes

ALPI

1734, 1735

Aminoacids

AMNA

1791, 1792

Amniotic Fluid Examination

AFE

1726, 1727

Ammonia

NH3

1791, 1792

Amylase

AMS

1558, 1559

Angiotensin converting enzyme

ACE

1791, 1792

Aspartate Aminotransferase

AST

1558, 1559

Beta Hydroxybutyrate

BHYB

1791, 1792

Bicarbonate

HCO3

1558, 1559

Bilirubin (all Fractions)

BILI

1558, 1559

Bilirubin (Neonatal)

BILN

1791, 1792

Blood Gases

GAS

1590, 1591

Breath Hydrogen Test

BHT

1963, 1964

Calcium (total, dialysed or ionized)

CA

1558, 1559

Calculus Analysis

CALC

1595, 1596

Catecholamines

CAT

1959, 1960

Cholinesterase

CHSE

1791, 1792

Chloride

CL

1558, 1559

Cholesterol

CHOL

1558, 1559

Cystine (Cysteine)

CYST

1791, 1792

Creatine Kinase

CK

1558, 1559

Creatine Kinase Isoenzymes

CKI

1558, 1559

\n```\n\n \n\n```html\n

Approved item name of test in Schedule

Abbreviation

Item numbers

Creatine Kinase Isoenzymes—Quantitative or Qualitative estimation by electrophoresis

CKIE

1734, 1735

Creatinine

C

1558, 1559

Cryoglobulins

CGLB

1575, 1576

Cryofibrinogen

CFIB

1575, 1576

Drug or Chemical Assays—Overdose

DRGO

1598, 1599

Drug Assays—Drug abuse treatment programme including urinary drug screen

DRGA

1627, 1628

Drug Assays—Therapeutic:

Antibiotics or antimicrobial chemotherapeutic agents (see under MICROBIOLOGY)

Amiodarone

AMIO

1712, 1713

Amitriptyline

AMIT

1712, 1713

Amylobarb

AMYL

1712, 1713

Barbitone

BARB

1712, 1713

Bromide

BRMD

1712, 1713

Butobarb

BUTO

1712, 1713

Carbamazepine (Tegretol)

CARB

1712, 1713

Chloral Hydrate

CHHY

1712, 1713

Chlorazepate

CHZP

1712, 1713

Chloropromazine

CHLO

1712, 1713

Chloroquine

CLOQ

1712, 1713

Cimetidine

CMTD

1712, 1713

Clobozam

CLOB

1712, 1713

Clonazepam (Rivotril)

CLON

1712, 1713

Cylosporin A

CLSA

1712, 1713

Desethyl Amiodarone

DEAM

1712, 1713

Desipramine

DESI

1712, 1713

Diazepam

DIAZ

1712, 1713

Digoxin

DIG

1712, 1713

Diphenylhydantoin (Dilantin)

DIL

1712, 1713

Disopyramide (Rythmodan)

DISO

1712, 1713

Doxepin

DOXE

1712, 1713

Ethosuximide (Zarontin)

ETHO

1712, 1713

Flecainide

FLEC

1712, 1713

Hydroxychloriquine

HOCQ

1712, 1713

Imipramine

IMIP

1712, 1713

Lignocaine

LIGN

1712, 1713

Methadone

MTDN

1712, 1713

Methotrexate

MTTA

1712, 1713

Methsuximide

MSUX

1712, 1713

Metronidazole

MRDZ

1712, 1713

Mexilitine (Mexitil)

MEX

1712, 1713

N Acetyl Procainamide

NAPC

1712, 1713

N Desalkyl Clobazan

NDAC

1712, 1713

N Desalkyldothiepin

NDOT

1712, 1713

N Desalkyl Doxepin

NDAD

1712, 1713

Nitrazepam

NITR

1712, 1713

Nordothiepin

NDIP

1712, 1713

Nortriptyline

NORT

1712, 1713

Oxazepam

OXAZ

1712, 1713

Paracetamol

PARA

1712, 1713

Paraquat

PARQ

1712, 1713

Approved item name of test in Schedule

Abbreviation

Item numbers

Pentabarb

PENT

1712, 1713

Perhexiline

PHEX

1712, 1713

Phenobarbitone

PHBA

1712, 1713

Phensoximide

PHEN

1712, 1713

Phenytoin

PHEY

1712, 1713

Prednisolone

PRED

1712, 1713

Primidone

PRIM

1712, 1713

Procainamide

PCAM

1712, 1713

Prominal

PROM

1712, 1713

Propanolol

PPNO

1712, 1713

Quinalbarb

QUIB

1712, 1713

Quinine

QNN

1712, 1713

Quinidine

QUIN

1712, 1713

Salicylate-Asprin

SALI

1712, 1713

Sotalol

SALL

1712, 1713

Stellazine

STEL

1712, 1713

Sulphadimidine

SPDD

1712, 1713

Sulthiame (Ospolot)

SUL

1712, 1713

Theophylline

THEO

1712, 1713

Thiopentone

TOPO

1712, 1713

Thioridazine

THIO

1712, 1713

Tocainide

TOCN

1712, 1713

Trimipramine

TRIM

1712, 1713

Valproate (Epilim)

VALP

1712, 1713

Vancomycin

VAN

1712, 1713

Warfarin

WFR

1712, 1713

Therapeutic drugs that are not listed above must be written in full.

Electrophoresis

To demonstrate protein classes or presence and amount of paraprotein classes

EPP1

1734, 1735

To demonstrate protein classes or presence and mount of paraprotein classes—concurrent collection

EPP2

1736, 1737

Elements:

Aluminium

AL

1871, 1872

Arsenic

AS

1871, 1872

Beryllium

BE

1871, 1872

Cadmium

CD

1871, 1872

Chromium

CR

1871, 1872

Copper

CU

1871, 1872

Gold

AU

1871, 1872

Lead

PB

1895, 1896

Manganese

MN

1871, 1872

Mercury

HG

1871, 1872

Nickel

NI

1871, 1872

Selenium

SE

1871, 1872

Strontium

SR

1871, 1872

Zinc

ZN

1791, 1792

Enzyme assays of solid tissue or tissues

ENZS

1969, 1970

Faecal Fat

FFAT

1963, 1964

Faecal Haemoglobin (chemical test)

FHC

1577, 1578

Faecal Haemoglobin (immunological test)

FHI

1579, 1580

Faecal Porphyrins (qualitative test)

FPR

1577, 1578

\n```\n\n \n\n| Approved item name of test in Schedule | Abbreviation | Item numbers |\n| -------------------------------------- | ------------ | ------------ |\n| Faecal Reducing Substances | FRS | 1577, 1578 |\n| Fructosamine | FRUC | 1558, 1559 |\n| Gamma Glutamyl Transpeptidase | GGT | 1558, 1559 |\n| Globulin | GLOB | 1558, 1559 |\n| Glucose | GLUC | 1558, 1559 |\n| Glucose Tolerance Test | GTT | 1558, 1559 |\n| Glycosylated Haemoglobin (Hb Ale) | GHB | 2043, 2044 |\n| HDL Cholesterol | HDLC | 2039, 2040 |\n| Hormones: | | |\n| Adrenocorticotrophic hormone | ACTH | 2021, 2024 |\n| Aldosterone | ALDS | 2021, 2024 |\n| Androstenedione | ANDR | 2021, 2024 |\n| Arginine | ARIN | 1991, 1992 |\n| C-Peptide | CPEP | 2021, 2024 |\n| Calcitonin | CALT | 2021, 2024 |\n| Cortisol | CORT | 2021, 2024 |\n| Cyclic AMP | CAMP | 2021, 2024 |\n| Dehydroepiandrosterone sulphate | DHEA | 2021, 2024 |\n| Dexamethasone | DXST | 1989, 1990 |\n| Dexamethazone Suppression test | DEXA | 2021, 2024 |\n| Dihydrotestosterone | DHTS | 2021, 2024 |\n| Follicular Stimulating Hormone | FSH | 2021, 2024 |\n| Gastrin | GAST | 2021, 2024 |\n| Glucagon | GLGO | 2021, 2024 |\n| Glucagon—stimulation test | GSTC | 1991, 1992 |\n| Gonadotrophin | GRHS | 1991, 1992 |\n| Growth Hormone | GH | 2021, 2024 |\n| Growth Hormone—exercise | GHSE | 1989, 1990 |\n| Growth Hormone—glucose | GHSG | 1989, 1990 |\n| Hormone Receptor Assay | HRA | 2037, 2038 |\n| Human Placental Lactogen | HPL | 2021, 2024 |\n| Hydroxyprogesterone | OHP | 2021, 2024 |\n| Insulin | INS | 2021, 2024 |\n| Insulin—stimulation test | INHY | 1991, 1992 |\n| L-Dopa | GHLD | 1989, 1990 |\n| Luteinizing Hormone | LH | 2021, 2024 |\n| Oestradiol | E2 | 2021, 2024 |\n| Oestriol | E3 | 2021, 2024 |\n| Oestrone | E1 | 2021, 2024 |\n| Parathyroid Hormone | PTH | 2021, 2024 |\n| Pentagastrin | PSTR | 1991, 1992 |\n| Progesterone | PROG | 2021, 2024 |\n| Prolactin | PROL | 2021, 2024 |\n| Renin | REN | 2021, 2024 |\n| Secretin | SSGR | 1991, 1992 |\n| Sex Hormone Binding Globulin | SHBG | 2021, 2024 |\n| Somatomedin | SOMA | 2021, 2024 |\n| Testosterone | TES | 2021, 2024 |\n| Thyroid Stimulating Hormone | TSH | 2021, 2024 |\n| Urine Steroid Fraction or Fractions | USF | 2021, 2024 |\n| Vasoactive Intestinal Peptide | VIP | 2021, 2024 |\n| Vasopressin | ADH | 2021, 2024 |\n| 11 Deoxycortisol | DCOR | 2021, 2024 |\n| HIAA (Hydroxyindoleacetic acid) | HIAA | 1791, 1792 |\n\n \n\n| Approved item name of test in Schedule | Abbreviation | Item numbers |\n| ------------------------------------------------------------------ | ------------ | ------------ |\n| Histamine | HIAM | 1791, 1792 |\n| HMMA (Hydroxy Methoxy Mandelic acid previously known as VMA) | HMMA | 1959, 1960 |\n| HVA (Homovanillic acid) | HVA | 1959, 1960 |\n| Hydroxyproline | HYDP | 1791, 1792 |\n| Intestinal disaccharidases | INTD | 1969, 1970 |\n| Iron Studies (Iron, Transferrin and Ferritin) | IS | 1752, 1753 |\n| Lactate | LACT | 1791, 1792 |\n| Lactate Dehydrogenase | LDH | 1558, 1559 |\n| Lactate Dehydrogenase Isoenzymes | LDI | 1734, 1735 |\n| Lamellar Body Phospholipid | LBPH | 1726, 1727 |\n| Lecithin/Sphingomyelin Ratio (Amniotic fluid) | LS | 1726, 1727 |\n| Lipase | LIP | 1558, 1559 |\n| Lithium | LI | 1558, 1559 |\n| Magnesium | MG | 1558, 1559 |\n| Metanephrines | MNEP | 1959, 1960 |\n| MHPG (Methoxy Hydroxy Phenyethylene Glycol) | MHPG | 1959, 1960 |\n| Osmolality, Serum or Urine | OSML | 1583, 1584 |\n| Oxalate | OXAL | 1791, 1792 |\n| PAA (Phenyl Acetic Acid) | PAA | 1959, 1960 |\n| Palmitic acid in amniotic fluid | PALM | 1726, 1727 |\n| pH measurement of body fluids other than urine | PH | 1575, 1576 |\n| Phosphate | PHOS | 1558, 1559 |\n| Phosphatidylglycerol | PTGL | 1726, 1727 |\n| Porphyrins (quantitative test, one or more fractions) | PR | 1959, 1960 |\n| Potassium | K | 1558, 1559 |\n| Prealbumin | PALB | 1738, 1739 |\n| Protein (Total) | PROT | 1558, 1559 |\n| Protein—Quantitative Estim. of Specific Protein: | | |\n| Alpha feto protein | AFP | 1738, 1739 |\n| Alpha—1 antitrypsin | AAT | 1738, 1739 |\n| Alpha—2 macroglobulin | AMAC | 1738, 1739 |\n| Beta-2 microglobulin | BMIC | 1738, 1739 |\n| C-l esterase inhibitor | CEI | 1738, 1739 |\n| Caeruloplasmin | CPLS | 1738, 1739 |\n| Ferritin | FERR | 1738, 1739 |\n| Haptoglobins | HGLB | 1738, 1739 |\n| Microalbumin | MALB | 1738, 1739 |\n| Transferrin | TRAN | 1738, 1739 |\n| Pyruvate | PVTE | 1791, 1792 |\n| Red Cell Folate and Serum B12 and, if required, Serum Folate | RCF | 1770, 1771 |\n| Serotonin | 5HT | 1791, 1792 |\n| Serum B12 | B12 | 1768, 1769 |\n| Serum Folate | FOL | 1768, 1769 |\n| Snake Venom | HISS | 1598, 1599 |\n| Sodium | NA | 1558, 1559 |\n| Synacthen Stimulation Test | SYNS | 2021, 2024 |\n| Thyroid Function Tests | TFT | 1983, 1984 |\n| Thyroid Stimulating Hormone (where not requested as part of a TFT) | TSH | 2021, 2024 |\n| Thyrotrophin Releasing Hormone Test | TRH | 1985, 1986 |\n| Total Free Fatty Acids | TFFA | 1791, 1792 |\n| Triglycerides | TRIG | 1558, 1559 |\n\n \n\n```html\n

Approved item name of test in Schedule

Abbreviation

Item numbers

Tumour Markers:

CA-125 antigen

C125

1738, 1739

CA-19.9 antigen

CA19

1738, 1739

CA-15.3 antigen

CA15

1738, 1739

Carcinoembryonic antigen

CEA

1738, 1739

Mammary Serum antigen

MSA

1738, 1739

Mucin-like carcinoma associated antigen

MCA

1738, 1739

Neuron specific enolase

NSEN

1738, 1739

Prostate specific antigen

PSA

1738, 1739

Prostatic acid phosphatase—one or more fractions

ACP

1738, 1739

SCC related antigen

SCCA

1738, 1739

Thyroglobulin

TGL

1738, 1739

Thyrotrophin Releasing Hormone Test

TRH

1985, 1986

Urate

URAT

1558, 1559

Urea

U

1558, 1559

Urine Bilirubin

UBIL

1575, 1576

Urine Cystine (Cysteine)

UCYS

1575, 1576

Urine Haemoglobin

UHB

1575, 1576

Urine Melanin (Melanogen)

UML

1575, 1576

Urine Myoglobin

UMY

1575, 1576

Urine Porphobilinogen

UPG

1575, 1576

Urine Porphyrins (qualitative test)

UPR

1575, 1576

Urine Urobilinogen

UUB

1575, 1576

Vitamin D

VITD

1786, 1787

Vitamin, Quantitative Estimation of Vitamins A, B1, B2, B3, B6, C or E

VIT

1780, 1783

Xylose

XYL

1791,1792

DIVISION 3—MICROBIOLOGY

Antibiotic and antimicrobial chemotherapeutic agents, quantitative assay

QAA

2235, 2236

Blood Culture

BC

2123, 2124

Chlamydia Investigation by Cultural Methods

CHLC

2139, 2140

Clostridium difficile

CLDT

2129, 2130

CSF antigens—Haemophilus influenzae, Streptococcus pneumoniae, Neisseria menigitidis, Group B Streptococcus

CSFA

2129, 2130

Cryptococcal antigen

CRYN

2129, 2130

Cultural Examination of faeces

FCS

2117, 2118

Hepatitis Serology:

Hepatitis Serology in Acute Hepatitis

HEP

2229, 2230

Hepatitis B Serology in follow up of proven Hepatitis B

HEPB

2231, 2232

Hepatitis B Surface antigen HBsAg

HBSA

2221, 2222

Hepatitis B Serology to define immune status

HEPI

2223, 2224

Herpes simplex Virus Investigation by Cultural Methods

HSVC

2139, 2140

Microbial Antibody Testing:

(IgG, IgM, IgA or Total antibodies may be tested against various organisms and are indicated by placing the letter G, M, A and T respectively on the end of the 3 letter abbreviation)

Actinomycetes

ACT

2181, 2182

Adenovirus

ADE

2181, 2182

Aspergillus

ASP

2181, 2182

Avian precipitins (Bird Fancier’s Disease)

APP

2181, 2182

\n```\n\n \n\n| Approved item name of test in Schedule | Abbreviation | Item numbers |\n| --------------------------------------------------------- | ------------ | ------------ |\n| Blastomyces | BLM | 2181, 2182 |\n| Bordetella pertussis | BOR | 2181, 2182 |\n| Borrelia Berghoffer | BOB | 2181, 2182 |\n| Brucella | BRU | 2181, 2182 |\n| Campylobacter jejuni | CAM | 2181, 2182 |\n| Candida | CAN | 2181, 2182 |\n| Chlamydia | CHL | 2181, 2182 |\n| Coccidioides | CCC | 2181, 2182 |\n| Coxsackie Bl-6 | COX | 2181, 2182 |\n| Cryptococcus | CRY | 2181, 2182 |\n| Cytomegalovirus | CMV | 2181, 2182 |\n| Cytomegalovirus Serology in Pregnancy | CMVP | 2145, 2146 |\n| Dengue | DEN | 2181, 2182 |\n| Diphtheria | DIP | 2181, 2182 |\n| Echinococcus | ECC | 2181, 2182 |\n| Echo-coxsackie group | ECH | 2181, 2182 |\n| Entamoeba histolytica | AMO | 2181, 2182 |\n| Epstein Barr Virus | EBV | 2181, 2182 |\n| Fluorescent Treponemal antibody—absorption test (FTA-ABS) | FTA | 2181, 2182 |\n| Haemophilus | HUS | 2181 2182 |\n| Hepatitis delta antibody—Anti-delta | HDA | 2181 2182 |\n| Histoplasma | HIP | 2181 2182 |\n| Hydatid | HYD | 2181 2182 |\n| Influenza A | FLA | 2181, 2182 |\n| Influenza B | FLB | 2181 2182 |\n| Legionella pneumophila—Serogroup 1 | LP1 | 2181, 2182 |\n| Legionella pneumophila—Serogroup 2 | LP2 | 2181, 2182 |\n| Leishmaniasis | LEI | 2181, 2182 |\n| Leptospira | LEP | 2181, 2182 |\n| Listeria | LIS | 2181, 2182 |\n| Measles | MEA | 2181, 2182 |\n| Micropolyspora faeni | MIC | 2181, 2182 |\n| Mumps | MUM | 2181, 2182 |\n| Murray Valley Encephalitis | MVE | 2181, 2182 |\n| Mycoplasma pneumoniae | MYC | 2181, 2182 |\n| Neisseria gonorrhoea | GON | 2181, 2182 |\n| Newcastle Disease | NCD | 2181, 2182 |\n| Parainfluenza 1 | PF1 | 2181, 2182 |\n| Parainfluenza 2 | PF2 | 2181, 2182 |\n| Parainfluenza 3 | PF3 | 2181, 2182 |\n| Paratyphi | PTY | 2181, 2182 |\n| Pertussis | PER | 2181, 2182 |\n| Pneumococcus | PCC | 2181, 2182 |\n| Poliomyelitis | PLO | 2181, 2182 |\n| Proteus OX 19 | POX | 2181, 2182 |\n| Proteus OXK | POK | 2181, 2182 |\n| Q fever | QFF | 2181, 2182 |\n| Rapid Plasma Reagin test | RPR | 2181, 2182 |\n| Respiratory Syncytial Virus | RSV | 2181, 2182 |\n| Ross River Virus | RRV | 2181, 2182 |\n| Rubella | RUB | 2181, 2182 |\n| Rubella Serology in Pregnancy | RUBP | 2145, 2146 |\n| Salmonella typhi (H) | SAH | 2181, 2182 |\n\n \n\n| Approved item name of test in Schedule | Abbreviation | Item numbers |\n| -------------------------------------------------------------------------------------------------------------------------------------------------- | ------------ | ------------ |\n| Salmonella typhi (O) | SAO | 2181, 2182 |\n| Schistosoma | STO | 2181, 2182 |\n| Streptococcal Serology-Anti-D-Nase B titre | ADNB | 2181, 2182 |\n| Streptococcal Serology-Anti-streptolysin O titre | ASOT | 2181, 2182 |\n| Tetanus | TET | 2181, 2182 |\n| Thermoactinomyces vulgaris | THE | 2181, 2182 |\n| Thermopolyspora | TPS | 2181, 2182 |\n| Toxocara | TOC | 2181, 2182 |\n| Toxoplasma | TOX | 2181, 2182 |\n| Toxoplasma Serology in Pregnancy | TOXP | 2145, 2146 |\n| Treponema pallidum haemagglutin test | TPHA | 2181, 2182 |\n| Trichonosis | TOS | 2181, 2182 |\n| Typhus, Weil-Felix | TYP | 2181, 2182 |\n| Varicella zoster | VCZ | 2181, 2182 |\n| Venereal Disease Research Laboratory (VDRL) | VDRL | 2181, 2182 |\n| Yersinia enterocolytica | YER | 2181, 2182 |\n| Microbial antibody tests which are not listed above must be written in full. | | |\n| Microbial Antigen Testing: | | |\n| Chlamydia | CHLY | 2133, 2134 |\n| Herpes simplex Virus | HSV | 2135, 2136 |\n| Microscopic examination of faeces for parasites | OCP | 2085, 2086 |\n| Microscopic examination of material other than blood | M | 2083, 2084 |\n| Microscopy and culture of material from nose, throat, eye and ear | MCS1 | 2087, 2088 |\n| Microscopy and culture of material from skin, superficial sites, urethra, vagina, cervix, sputum or rectum | MCS2 | 2089, 2090 |\n| Microscopy and culture of material from post operative wounds, aspirations of body cavities, synovial fluid, CSF and operative or biopsy specimens | MCS3 | 2098, 2099 |\n| Microscopy and culture of sputum for mycobacteria | AFB | 2119, 2120 |\n| Respiratory Syncytial Virus | RSVN | 2129, 2130 |\n| Urine microscopy, culture, identification and sensitivity | UMCS | 2127, 2128 |\n| Varicella zoster | VCZN | 2129, 2130 |\n| DIVISION 4—IMMUNOLOGY | | |\n| Specific IgG or IgE antibodies | ALLG | 2259, 2260 |\n| Antibodies to Tissue Antigens: | | |\n| Acetylcholine receptor | ARA | 2271, 2274 |\n| Adrenal cell | ADR | 2271, 2274 |\n| Cardiolipin | ACL | 2271, 2274 |\n| Centromere | ACA | 2271, 2274 |\n| Gliadin IgA | GLIA | 2271, 2274 |\n| Gastric parietal cell | PCA | 2271, 2274 |\n| Glomerular basement membrane | GBA | 2271, 2274 |\n| Insulin Receptor Antibodies | INSA | 2271, 2274 |\n| Intercellular Cement Substance of Skin | ICCS | 2271, 2274 |\n| Jo-1 | JO1 | 2271, 2274 |\n| Keratin | KERA | 2271, 2274 |\n| Liver/Kidney microsomes | LKA | 2271, 2274 |\n| Mitochondria | MA | 2271, 2274 |\n| Parathyroid cell | PTHA | 2271, 2274 |\n| PM-1 | PM1 | 2271, 2274 |\n\n \n\n```html\n

Approved item name of test in Schedule

Abbreviation

Item numbers

Reticulin

RCA

2271, 2274

SCL 70

SCL

2271, 2274

Skeletal muscle

SLA

2271, 2274

Skin basement membrane

SKA

2271, 2274

Smooth muscle

SMA

2271, 2274

Thyroid microsomal

TMA

2271, 2274

TSH Receptor Antibody test

TSHA

2271, 2274

Tissue antigens which are not listed above must be written in full

Antibodies to Nuclear Antigens—detection

ANA

2261, 2262

Antibodies to Nuclear Antigens—quantitation and Measurement of DNA Binding if Positive ANA

ANAP

2263, 2266

Antibodies to Extractable Nuclear Antigens—detection

ENA

2267, 2268

Antibodies to Extractable Nuclear Antigens— characterization of antibodies if positive ENA

ENAP

2269, 2270

Complement Total, C3 or C4

COM

2289, 2290

Other complements must be specified

HLA Typing, comprising A, B, C and DR Phenotypes

HLA

2321, 2322

HLA Typing, 1 or more antigens

HLAN

2323, 2324

Immunoglobulins G, A, M or D

IG

2245, 2246

Immunoglobulin G, Subclasses 1-4

SIGG

2255, 2256

Immunoglobulin E

IGE

2257, 2258

Leucocyte Fractionation

LF

2313, 2314

Leucocyte Functional Tests

LFF

2315, 2316

Leucocyte Surface Markers to assess lymphoid populations

LSML

2317, 2318

Leucocyte Surface Markers in investigation of probable haematological malignancy

LSMH

2319, 2320

Mantoux Test

MANT

2325, 2326

Paraprotein Investigation by Immuno-electrophoreses or immunofixation

PPRO

2239, 2240

Paraprotein Investigation on Concurrently Collected Serum and Urine

PPSU

2241, 2242

Rheumatoid Factor (all tests including Latex test)

RF

2281, 2282

Rheumatoid Factor quantitation

RFQ

2283, 2284

DIVISION 5—HISTOPATHOLOGY

Electron microscopy of biopsy material

EM

2333, 2337

Histopathology of biopsy material

HIST

2327, 2328

Immediate frozen section diagnosis of biopsy material

FS

2329, 2330

Immunohistochemical investigation of biopsy material

IHIS

2331, 2332

DIVISION 6—CYTOPATHOLOGY

Cytology from cervix or vagina

CXCY

2338, 2339

Cytology from skin, nipple discharge, lip, mouth, nose or anus

SMCY

2340, 2341

Cytology from body fluids, sputum (1 specimen), washings or brushings

BFCY

2340, 2341

Cytology from 3 sputum or urine specimens

SPCY

2348, 2349

Cytology from fine needle aspiration of solid tissues

FNCY

2350, 2351

Cytology from fine needle aspiration of solid tissues— aspiration or attendance by Pathologist

FNCP

2355, 2356

DIVISION 7—CYTOGENETICS

Chromosome studies

CS

2360, 2361

\n```\n\n \n\n```html\n

Approved item name of test in Schedule

Abbreviation

Item numbers

Chromosome studies of blood

CSB

2363, 2364

Chromosome identification by banding techniques

CSI

2365, 2366

DIVISION 8—INFERTILITY AND PREGNANCY TESTS

Semen examination for spermatozoa

SES

2370, 2371

Huhner’s test

HT

2370, 2371

Semen examination

SEE

2372, 2373

Sperm antibodies

SAB

2377, 2378

Sperm penetrating ability

SPA

2377, 2378

Chorionic gonadotrophin for pregnancy diagnosis

HCG

2379, 2380

Chorionic gonadotrophin for diagnosis of specified conditions

HCGD

2384, 2385

\n```\n\nNOTE\n\n1\\. Notified in the Commonwealth of Australia Gazette on 31 October 1990.","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":1640},"content_quality":"ok","complexity_score":8,"scope_assessment":{"changed":false,"description":"This regulation remains strictly focused on its original purpose: prescribing the specific pathology services, fees, and claiming rules for the 1990-91 financial year under the Health Insurance Act 1973. It repeals and replaces the previous year's equivalent regulations without expanding beyond the scope of setting annual pathology benefits."},"complexity_factors":["Over 250 individual line items (item numbers) covering 9 different pathology specialties","Dual fee structure with different rates for specialist pathologists (SP items) and non-specialist providers (OP items)","Complex bundling rules where one test can 'subsume' another, or multiple tests count as a single service","16 detailed Rules of Interpretation governing how items interact","Extensive cross-referencing between items (e.g., 'including any service specified in item 1163')","Numerous frequency restrictions limiting how often tests can be claimed (e.g., 'maximum of 4 estimations in any 12 month period')","Highly technical medical and laboratory terminology throughout"],"plain_english_summary":"**What this legislation does**\n\nThis regulation establishes the **Pathology Services Table** for Australia's national health insurance scheme (Medicare) for the 1990-91 financial year. It sets out exactly which laboratory tests are subsidised by the government, how much doctors and laboratories get paid for each test, and the rules for claiming these benefits.\n\n**Key points:**\n\n* **The "}},"importantCases":[],"_links":{"self":"/api/acts/health-insurance-1990-91-pathology-services-table-regulations","history":"/api/acts/health-insurance-1990-91-pathology-services-table-regulations/history","analysis":"/api/acts/health-insurance-1990-91-pathology-services-table-regulations/analysis","conflicts":"/api/acts/health-insurance-1990-91-pathology-services-table-regulations/conflicts","importantCases":"/api/acts/health-insurance-1990-91-pathology-services-table-regulations/important-cases","documents":"/api/acts/health-insurance-1990-91-pathology-services-table-regulations/documents"}}